Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells

1.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

2.

Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. https://doi.org/10.1093/neuonc/not151CrossRefPubMedPubMedCentral

3.

Tamimi AF, Juweid M (2017) Epidemiology and outcome of glioblastoma. In: Glioblastoma. Codon Publications. https://doi.org/10.15586/codon.glioblastoma.2017.ch8

4.

Holland EC (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 97(12):6242–6244. https://doi.org/10.1073/pnas.97.12.6242CrossRefPubMedPubMedCentral

5.

Fernandes C, Costa A, Osório L, Lago RC, Linhares P, Carvalho B, Caeiro C (2017) Current standards of care in glioblastoma therapy. In: Glioblastoma. Codon Publications. https://doi.org/10.15586/codon.glioblastoma.2017.ch11

6.

Hou LC, Veeravagu A, Hsu AR, Tse VC (2006) Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 20(4):E5. https://doi.org/10.3171/foc.2006.20.4.2CrossRefPubMed

7.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330CrossRefPubMed

8.

Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H (2014) Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 4:126. https://doi.org/10.3389/fonc.2014.00126CrossRefPubMedPubMedCentral

9.

De Vleeschouwer S, Bergers G (2017) Glioblastoma: to target the tumor cell or the microenvironment? In: Glioblastoma. Codon Publications. https://doi.org/10.15586/codon.glioblastoma.2017.ch16

10.

Audia A, Conroy S, Glass R, Bhat KP (2017) The impact of the tumor microenvironment on the properties of glioma stem-like cells. Front Oncol 7:143PubMedPubMedCentral

11.

McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168(4):613–628. https://doi.org/10.1016/j.cell.2017.01.018CrossRefPubMed

12.

Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M (2011) Tumour evolution inferred by single-cell sequencing. Nature 472(7341):90–94. https://doi.org/10.1038/nature09807CrossRefPubMedPubMedCentral

13.

Prasetyanti PR, Medema JP (2017) Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer 16(1):41. https://doi.org/10.1186/s12943-017-0600-4CrossRefPubMedPubMedCentral

14.

Alves TR, Lima FR, Kahn SA, Lobo D, Dubois LG, Soletti R, Borges H, Neto VM (2011) Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci 89(15–16):532–539. https://doi.org/10.1016/j.lfs.2011.04.022CrossRefPubMed

15.

Bernstock JD, Mooney JH, Ilyas A, Chagoya G, Estevez-Ordonez D, Ibrahim A, Nakano I (2019) Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications. J Neurosurg. https://doi.org/10.3171/2019.5.JNS19364CrossRefPubMed

16.

Brown DV, Stylli SS, Kaye AH, Mantamadiotis T (2019) Multilayered heterogeneity of glioblastoma stem cells: biological and clinical significance. Adv Exp Med Biol 1139:1–21. https://doi.org/10.1007/978-3-030-14366-4_1CrossRefPubMed

17.

Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavare S (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 110(10):4009–4014. https://doi.org/10.1073/pnas.1219747110CrossRefPubMedPubMedCentral

18.

Lee JK, Wang J, Sa JK, Ladewig E, Lee HO, Lee IH, Kang HJ, Rosenbloom DS, Camara PG, Liu Z, van Nieuwenhuizen P, Jung SW, Choi SW, Kim J, Chen A, Kim KT, Shin S, Seo YJ, Oh JM, Shin YJ, Park CK, Kong DS, Seol HJ, Blumberg A, Lee JI, Iavarone A, Park WY, Rabadan R, Nam DH (2017) Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet 49(4):594–599. https://doi.org/10.1038/ng.3806CrossRefPubMedPubMedCentral

19.

Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN (2015) Cancer stem cells in glioblastoma. Genes Dev 29(12):1203–1217. https://doi.org/10.1101/gad.261982.115CrossRefPubMedPubMedCentral

20.

Qiang L, Yang Y, Ma Y-J, Chen F-H, Zhang L-B, Liu W, Qi Q, Lu N, Tao L, Wang X-T (2009) Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 279(1):13–21PubMed

21.

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828PubMed

22.

Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412):522–526. https://doi.org/10.1038/nature11287CrossRefPubMedPubMedCentral

23.

Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13(7):1238–1241. https://doi.org/10.1038/sj.cdd.4401872CrossRefPubMed

24.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760. https://doi.org/10.1038/nature05236CrossRefPubMed

25.

Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell–like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Can Res 66(16):7843–7848

26.

Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, Shimizu K (2009) Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest 27(9):901–908PubMed

27.

Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C (2011) Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci 108(38):16062–16067PubMedPubMedCentral

28.

Cheng L, Bao S, Rich JN (2010) Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 80(5):654–665PubMedPubMedCentral

29.

Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE, Bijangi-Vishehsaraei K (2016) Emerging targets for glioblastoma stem cell therapy. J Biomed Res 30(1):19PubMed

30.

Hosein AN, Lim YC, Day B, Stringer B, Rose S, Head R, Cosgrove L, Sminia P, Fay M, Martin JH (2015) The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. J Neurooncol 122(2):263–271PubMed

31.

Francis JM, Zhang CZ, Maire CL, Jung J, Manzo VE, Adalsteinsson VA, Homer H, Haidar S, Blumenstiel B, Pedamallu CS, Ligon AH, Love JC, Meyerson M, Ligon KL (2014) EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov 4(8):956–971. https://doi.org/10.1158/2159-8290.CD-13-0879CrossRefPubMedPubMedCentral

32.

Perus LJM, Walsh LA (2019) Microenvironmental Heterogeneity in Brain Malignancies. Front Immunol 10:2294. https://doi.org/10.3389/fimmu.2019.02294CrossRefPubMedPubMedCentral

33.

Baslan T, Kendall J, Ward B, Cox H, Leotta A, Rodgers L, Riggs M, D'Italia S, Sun G, Yong M, Miskimen K, Gilmore H, Saborowski M, Dimitrova N, Krasnitz A, Harris L, Wigler M, Hicks J (2015) Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. Genome Res 25(5):714–724. https://doi.org/10.1101/gr.188060.114CrossRefPubMedPubMedCentral

34.

Gawad C, Koh W, Quake SR (2014) Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc Natl Acad Sci U S A 111(50):17947–17952. https://doi.org/10.1073/pnas.1420822111CrossRefPubMedPubMedCentral

35.

Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X, Li F, Wu K, Liang J, Shao D, Wu H, Ye X, Ye C, Wu R, Jian M, Chen Y, Xie W, Zhang R, Chen L, Liu X, Yao X, Zheng H, Yu C, Li Q, Gong Z, Mao M, Yang X, Yang L, Li J, Wang W, Lu Z, Gu N, Laurie G, Bolund L, Kristiansen K, Wang J, Yang H, Li Y, Zhang X, Wang J (2012) Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148(5):873–885. https://doi.org/10.1016/j.cell.2012.02.028CrossRefPubMed

36.

Klevebring D, Rosin G, Ma R, Lindberg J, Czene K, Kere J, Fredriksson I, Bergh J, Hartman J (2014) Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo. Breast Cancer Res 16(4):R72. https://doi.org/10.1186/bcr3687CrossRefPubMedPubMedCentral

37.

Li Y, Xu X, Song L, Hou Y, Li Z, Tsang S, Li F, Im KM, Wu K, Wu H, Ye X, Li G, Wang L, Zhang B, Liang J, Xie W, Wu R, Jiang H, Liu X, Yu C, Zheng H, Jian M, Nie L, Wan L, Shi M, Sun X, Tang A, Guo G, Gui Y, Cai Z, Li J, Wang W, Lu Z, Zhang X, Bolund L, Kristiansen K, Wang J, Yang H, Dean M, Wang J (2012) Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. Gigascience 1(1):12. https://doi.org/10.1186/2047-217X-1-12CrossRefPubMedPubMedCentral

38.

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suva ML, Regev A, Bernstein BE (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344(6190):1396–1401. https://doi.org/10.1126/science.1254257CrossRefPubMedPubMedCentral

39.

Potter NE, Ermini L, Papaemmanuil E, Cazzaniga G, Vijayaraghavan G, Titley I, Ford A, Campbell P, Kearney L, Greaves M (2013) Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res 23(12):2115–2125. https://doi.org/10.1101/gr.159913.113CrossRefPubMedPubMedCentral

40.

Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y (2015) Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. Genome Biol 16:66. https://doi.org/10.1186/s13059-015-0636-yCrossRefPubMedPubMedCentral

41.

Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, Navin NE (2014) Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512(7513):155–160. https://doi.org/10.1038/nature13600CrossRefPubMedPubMedCentral

42.

Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, He W, Zeng L, Xing M, Wu R, Jiang H, Liu X, Cao D, Guo G, Hu X, Gui Y, Li Z, Xie W, Sun X, Shi M, Cai Z, Wang B, Zhong M, Li J, Lu Z, Gu N, Zhang X, Goodman L, Bolund L, Wang J, Yang H, Kristiansen K, Dean M, Li Y, Wang J (2012) Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148(5):886–895. https://doi.org/10.1016/j.cell.2012.02.025CrossRefPubMedPubMedCentral

43.

Yu C, Yu J, Yao X, Wu WK, Lu Y, Tang S, Li X, Bao L, Li X, Hou Y, Wu R, Jian M, Chen R, Zhang F, Xu L, Fan F, He J, Liang Q, Wang H, Hu X, He M, Zhang X, Zheng H, Li Q, Wu H, Chen Y, Yang X, Zhu S, Xu X, Yang H, Wang J, Zhang X, Sung JJ, Li Y, Wang J (2014) Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. Cell Res 24(6):701–712. https://doi.org/10.1038/cr.2014.43CrossRefPubMedPubMedCentral

44.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7):3983–3988. https://doi.org/10.1073/pnas.0530291100CrossRefPubMedPubMedCentral

45.

Shipitsin M, Polyak K (2008) The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 88(5):459–463. https://doi.org/10.1038/labinvest.2008.14CrossRefPubMedPubMedCentral

46.

Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138(5):822–829. https://doi.org/10.1016/j.cell.2009.08.017CrossRefPubMed

47.

Engelmann K, Shen H, Finn OJ (2008) MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res 68(7):2419–2426. https://doi.org/10.1158/0008-5472.CAN-07-2249CrossRefPubMed

48.

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. https://doi.org/10.1016/j.stem.2007.08.014CrossRefPubMedPubMedCentral

49.

Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101(39):14228–14233. https://doi.org/10.1073/pnas.0400067101CrossRefPubMedPubMedCentral

50.

Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104(24):10158–10163. https://doi.org/10.1073/pnas.0703478104CrossRefPubMedPubMedCentral

51.

Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, Sopp P, Norfo R, Rodriguez-Meira A, Ashley N, Jamieson L, Vyas P, Anderson K, Segerstolpe A, Qian H, Olsson-Stromberg U, Mustjoki S, Sandberg R, Jacobsen SEW, Mead AJ (2017) Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med 23(6):692–702. https://doi.org/10.1038/nm.4336CrossRefPubMed

52.

O'Brien CA, Kreso A, Jamieson CH (2010) Cancer stem cells and self-renewal. Clin Cancer Res 16(12):3113–3120. https://doi.org/10.1158/1078-0432.CCR-09-2824CrossRefPubMed

53.

Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23(43):7274–7282. https://doi.org/10.1038/sj.onc.1207947CrossRefPubMed

54.

Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111. https://doi.org/10.1038/35102167CrossRefPubMed

55.

Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, Abel U, Arens A, Weichert W, Brand K, Koch M, Weitz J, Schmidt M, von Kalle C, Glimm H (2011) Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9(4):357–365. https://doi.org/10.1016/j.stem.2011.08.010CrossRefPubMed

56.

Bai X, Ni J, Beretov J, Graham P, Li Y (2018) Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev 69:152–163. https://doi.org/10.1016/j.ctrv.2018.07.004CrossRefPubMed

57.

Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121(1):396–409. https://doi.org/10.1172/JCI35721CrossRefPubMed

58.

Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, Pereira K, Karamboulas C, Moghal N, Rajeshkumar NV, Hidalgo M, Tsao M, Ailles L, Waddell TK, Maitra A, Neel BG, Matsui W (2010) Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 7(3):279–282. https://doi.org/10.1016/j.stem.2010.08.009CrossRefPubMedPubMedCentral

59.

Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65(14):6207–6219. https://doi.org/10.1158/0008-5472.CAN-05-0592CrossRefPubMed

60.

Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C (2008) Identification of cells initiating human melanomas. Nature 451(7176):345PubMedPubMedCentral

61.

Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141(4):583–594PubMedPubMedCentral

62.

Eun K, Ham SW, Kim H (2017) Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Rep 50(3):117–125. https://doi.org/10.5483/bmbrep.2017.50.3.222CrossRefPubMedPubMedCentral

63.

Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS, Crawford H, Dufour JU, Botchkina WLAJYYGI (2009) Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Cancer Genom Proteom 6(1):19–29

64.

Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1):62–73. https://doi.org/10.1016/j.cell.2009.12.007CrossRefPubMed

65.

Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, Gilmore H, Tung N, Naber SP, Schnitt S, Lander ES, Kuperwasser C (2011) Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8(2):149–163. https://doi.org/10.1016/j.stem.2010.12.007CrossRefPubMedPubMedCentral

66.

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67(9):4010–4015. https://doi.org/10.1158/0008-5472.CAN-06-4180CrossRefPubMed

67.

Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8(10):806–823. https://doi.org/10.1038/nrd2137CrossRefPubMed

68.

Floor S, Van Staveren W, Larsimont D, Dumont JE, Maenhaut C (2011) Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating–cancer stem cells: distinct, overlapping or same populations. Oncogene 30(46):4609–4621PubMed

69.

Hope KJ, Jin L, Dick JE (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5(7):738–743. https://doi.org/10.1038/ni1080CrossRefPubMed

70.

Luo M, Wicha MS (2015) Metabolic plasticity of cancer stem cells. Oncotarget 6(34):35141PubMedPubMedCentral

71.

Snyder V, Reed-Newman TC, Arnold L, Thomas SM, Anant S (2018) Cancer stem cell metabolism and potential therapeutic targets. Front Oncol 8:203PubMedPubMedCentral

72.

Ye F, Zhang Y, Liu Y et al (2013) Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. PLoS One 8(11):e80397. https://doi.org/10.1371/journal.pone.0080397CrossRefPubMedPubMedCentral

73.

Brooks MD, Burness ML, Wicha MS (2015) Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell 17(3):260–271. https://doi.org/10.1016/j.stem.2015.08.014CrossRefPubMedPubMedCentral

74.

Friedmann-Morvinski D, Verma IM (2014) Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep 15(3):244–253PubMedPubMedCentral

75.

Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE, Bijangi-Vishehsaraei K (2015) Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes Dis 2(2):152–163. https://doi.org/10.1016/j.gendis.2015.02.001CrossRefPubMedPubMedCentral

76.

Abbaszadegan MR, Bagheri V, Razavi MS, Momtazi AA, Sahebkar A, Gholamin M (2017) Isolation, identification, and characterization of cancer stem cells: A review. J Cell Physiol 232(8):2008–2018. https://doi.org/10.1002/jcp.25759CrossRefPubMed

77.

Ho DW, Tsui YM, Sze KM, Chan LK, Cheung TT, Lee E, Sham PC, Tsui SK, Lee TK, Ng IO (2019) Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. Cancer Lett 459:176–185. https://doi.org/10.1016/j.canlet.2019.06.002CrossRefPubMed

78.

Humphries HN, Wickremesekera SK, Marsh RW, Brasch HD, Mehrotra S, Tan ST, Itinteang T (2017) Characterization of cancer stem cells in colon adenocarcinoma metastasis to the liver. Front Surg 4:76. https://doi.org/10.3389/fsurg.2017.00076CrossRefPubMed

79.

Jonasson E, Ghannoum S, Persson E, Karlsson J, Kroneis T, Larsson E, Landberg G, Stahlberg A (2019) Identification of breast cancer stem cell related genes using functional cellular assays combined with single-cell RNA sequencing in MDA-MB-231 cells. Front Genet 10:500. https://doi.org/10.3389/fgene.2019.00500CrossRefPubMedPubMedCentral

80.

Parte SC, Batra SK, Kakar SS (2018) Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors. J Ovarian Res 11(1):69. https://doi.org/10.1186/s13048-018-0439-3CrossRefPubMedPubMedCentral

81.

Pan S, Zhan Y, Chen X, Wu B, Liu B (2019) Identification of biomarkers for controlling cancer stem cell characteristics in bladder cancer by network analysis of transcriptome data stemness indices. Front Oncol 9:613. https://doi.org/10.3389/fonc.2019.00613CrossRefPubMedPubMedCentral

82.

Rodriguez-Meira A, Buck G, Clark SA, Povinelli BJ, Alcolea V, Louka E, McGowan S, Hamblin A, Sousos N, Barkas N, Giustacchini A, Psaila B, Jacobsen SEW, Thongjuea S, Mead AJ (2019) Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing. Mol Cell. https://doi.org/10.1016/j.molcel.2019.01.009CrossRefPubMedPubMedCentral

83.

Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS (2010) A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17(4):362–375. https://doi.org/10.1016/j.ccr.2009.12.049CrossRefPubMed

84.

Piccirillo SG, Combi R, Cajola L, Patrizi A, Redaelli S, Bentivegna A, Baronchelli S, Maira G, Pollo B, Mangiola A, DiMeco F, Dalpra L, Vescovi AL (2009) Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 28(15):1807–1811. https://doi.org/10.1038/onc.2009.27CrossRefPubMed

85.

Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, Wischhusen J, Spang R, Storch A, Beier CP (2010) Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70(5):2030–2040. https://doi.org/10.1158/0008-5472.CAN-09-1707CrossRefPubMed

86.

Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, Um JY, Kim WK, Lee JK, Park J, Kim EH, Lee JH, Lee JH, Chung WS, Ju YS, Park SH, Chang JH, Kang SG, Lee JH (2018) Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560(7717):243–247. https://doi.org/10.1038/s41586-018-0389-3CrossRefPubMed

87.

Facchino S, Abdouh M, Bernier G (2011) Brain cancer stem cells: current status on glioblastoma multiforme. Cancers 3(2):1777–1797PubMedPubMedCentral

88.

Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, VandenBerg S, Alvarez-Buylla A (2006) PDGFRα-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 51(2):187–199PubMed

89.

Auffinger B, Tobias A, Han Y, Lee G, Guo D, Dey M, Lesniak M, Ahmed A (2014) Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ 21(7):1119PubMedPubMedCentral

90.

Liu YC, Lee IC, Chen PY (2018) Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype. J Neurooncol 137(3):511–522. https://doi.org/10.1007/s11060-018-2763-2CrossRefPubMed

91.

Suva ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE (2014) Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157(3):580–594. https://doi.org/10.1016/j.cell.2014.02.030CrossRefPubMedPubMedCentral

92.

Nduom EK-E, Hadjipanayis CG, Van Meir EG (2012) Glioblastoma cancer stem-like cells–implications for pathogenesis and treatment. Cancer J (Sudbury, Mass) 18(1):100

93.

Yan X, Ma L, Yi D, Yoon JG, Diercks A, Foltz G, Price ND, Hood LE, Tian Q (2011) A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A 108(4):1591–1596. https://doi.org/10.1073/pnas.1018696108CrossRefPubMedPubMedCentral

94.

Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G (2013) CD133 is essential for glioblastoma stem cell maintenance. Stem cells 31(5):857–869PubMed

95.

Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J (2008) Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Experim Clin Cancer Res 27(1):85

96.

Gangemi RMR, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27(1):40–48PubMed

97.

Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, Zhang Y, Ling EA, Gao J, Hao A (2011) Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 59(4):763–775. https://doi.org/10.1111/j.1365-2559.2011.03993.xCrossRefPubMed

98.

Lee Y, Kim KH, Kim DG et al (2015) FoxM1 promotes stemness and radio-resistance of glioblastoma by regulating the master stem cell regulator Sox2. PLoS One 10(10):e0137703. https://doi.org/10.1371/journal.pone.0137703CrossRefPubMedPubMedCentral

99.

Jin X, Jin X, Jung J-E, Beck S, Kim H (2013) Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun 433(4):496–501PubMed

100.

Iacopino Fortunata et al (2014) Isolation of cancer stem cells from three human glioblastoma cell lines: characterization of two selected clones. PloS one 9(8):e105166. https://doi.org/10.1371/journal.pone.0105166CrossRefPubMedPubMedCentral

101.

Lagadec C, Vlashi E, Frohnen P, Alhiyari Y, Chan M, Pajonk F (2014) The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer-and glioma-initiating cells. Stem Cells 32(1):135–144PubMedPubMedCentral

102.

Venugopal C, Li N, Wang X, Manoranjan B, Hawkins C, Gunnarsson T, Hollenberg R, Klurfan P, Murty N, Kwiecien J (2012) Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells. Stem Cell Res 8(2):141–153PubMed

103.

Sibin M, Lavanya C, Bhat DI, Rao N, Geethashree N, Vibhuti W, Chetan G (2015) CD133 and BMI1 expressions and its prognostic role in primary glioblastoma. J Genet 94(4):689–696PubMed

104.

Vora P, Seyfrid M, Venugopal C, Qazi MA, Salim S, Isserlin R, Subapanditha M, O’Farrell E, Mahendram S, Singh M (2019) Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. J Neurooncol 143(3):417–428PubMed

105.

Zhang L, Yan Y, Jiang Y, Cui Y, Zou Y, Qian J, Luo C, Lu Y, Wu X (2015) The expression of SALL4 in patients with gliomas: high level of SALL4 expression is correlated with poor outcome. J Neurooncol 121(2):261–268PubMed

106.

Bradshaw A, Wickremsekera A, Tan ST, Peng L, Davis PF, Itinteang T (2016) Cancer stem cell hierarchy in glioblastoma multiforme. Front Surgery 3:21

107.

Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y, Cao X, Ling EA, Hao A (2009) Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia 57(7):724–733. https://doi.org/10.1002/glia.20800CrossRefPubMed

108.

Ikushima H, Todo T, Ino Y, Takahashi M, Saito N, Miyazawa K, Miyazono K (2011) Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J Biol Chem 286(48):41434–41441PubMedPubMedCentral

109.

Sherry MM, Reeves A, Wu JK, Cochran BH (2009) STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27(10):2383–2392. https://doi.org/10.1002/stem.185CrossRefPubMedPubMedCentral

110.

Niu CS, Yang Y, Cheng CD (2013) MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. Int J Oncol 42(5):1533–1540. https://doi.org/10.3892/ijo.2013.1844CrossRefPubMedPubMedCentral

111.

Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I, Ruiz i Altaba A (2010) NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J 29(15):2659–2674. https://doi.org/10.1038/emboj.2010.137CrossRefPubMedPubMedCentral

112.

Herms JW, von Loewenich FD, Behnke J, Markakis E, Kretzschmar HA (1999) c-myc oncogene family expression in glioblastoma and survival. Surg Neurol 51(5):536–542. https://doi.org/10.1016/s0090-3019(98)00028-7CrossRefPubMed

113.

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, dePinho RA (2008) Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol 73:427–437. https://doi.org/10.1101/sqb.2008.73.047CrossRefPubMed

114.

Field M, Alvarez A, Bushnev S, Sugaya K (2010) Embryonic stem cell markers distinguishing cancer stem cells from normal human neuronal stem cell populations in malignant glioma patients. Clin Neurosurg 57:151–159PubMed

115.

Cheng J-X, Liu B-L, Zhang X (2009) How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev 35(5):403–408PubMed

116.

Piccirillo S, Vescovi A (2007) Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. In: Cancer Stem Cells. Springer, pp 59–81. https://doi.org/10.1007/2789_2007_044

117.

Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Kotliarova S, Kotliarov Y, Walling J, Ahn S, Kim M, Totonchy M, Cusack T, Ene C, Ma H, Su Q, Zenklusen JC, Zhang W, Maric D, Fine HA (2008) Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13(1):69–80. https://doi.org/10.1016/j.ccr.2007.12.005CrossRefPubMedPubMedCentral

118.

Sandberg CJ, Altschuler G, Jeong J, Stromme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA (2013) Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome. Exp Cell Res 319(14):2230–2243. https://doi.org/10.1016/j.yexcr.2013.06.004CrossRefPubMed

119.

Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S (2010) Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting. Protein Cell 1(7):638–655PubMedPubMedCentral

120.

Pang B, Xu J, Hu J, Guo F, Wan L, Cheng M, Pang L (2019) Single-cell RNA-seq reveals the invasive trajectory and molecular cascades underlying glioblastoma progression. Mol Oncol 13(12):2588–2603. https://doi.org/10.1002/1878-0261.12569CrossRefPubMedPubMedCentral

121.

Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29(34):4482PubMedPubMedCentral

122.

Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, Venteicher AS, Hebert CH, Carey CD, Rodig SJ, Shareef SJ, Najm FJ, van Galen P, Wakimoto H, Cahill DP, Rich JN, Aster JC, Suva ML, Patel AP, Bernstein BE (2017) Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell. https://doi.org/10.1016/j.stem.2016.11.003CrossRefPubMed

123.

Tamura K, Aoyagi M, Ando N, Ogishima T, Wakimoto H, Yamamoto M, Ohno K (2013) Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. J Neurosurg 119(5):1145–1155PubMed

124.

Zhou D, Alver BM, Li S, Hlady RA, Thompson JJ, Schroeder MA, Lee JH, Qiu J, Schwartz PH, Sarkaria JN, Robertson KD (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19(1):43. https://doi.org/10.1186/s13059-018-1420-6CrossRefPubMedPubMedCentral

125.

Murata H, Yoshimoto K, Hatae R, Akagi Y, Mizoguchi M, Hata N, Kuga D, Nakamizo A, Amano T, Sayama T, Iihara K (2015) Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression. J Neurooncol 125(1):33–41. https://doi.org/10.1007/s11060-015-1886-yCrossRefPubMed

126.

Ayer DE (1999) Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell Biol 9(5):193–198PubMed

127.

Spange S, Wagner T, Heinzel T, Krämer OH (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41(1):185–198PubMed

128.

Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang S-W (2010) Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10(6):935–954PubMedPubMedCentral

129.

Li Y, Seto E (2016) HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a026831CrossRefPubMedPubMedCentral

130.

Marampon F, Megiorni F, Camero S, Crescioli C, McDowell HP, Sferra R, Vetuschi A, Pompili S, Ventura L, De Felice F (2017) HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells. Cancer Lett 397:1–11PubMed

131.

Santos-Barriopedro I, Li Y, Bahl S, Seto E (2019) HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1. Genes Cancer 10(5–6):119–133. https://doi.org/10.18632/genesandcancer.197CrossRefPubMedPubMedCentral

132.

Pillonel V, Reichert N, Cao C, Heideman MR, Yamaguchi T, Matthias G, Tzankov A, Matthias P (2016) Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma. Sci Rep 6:37772PubMedPubMedCentral

133.

Pinazza M, Ghisi M, Minuzzo S, Agnusdei V, Fossati G, Ciminale V, Pezzè L, Ciribilli Y, Pilotto G, Venturoli C (2018) Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells. Oncogene 37(28):3839–3851PubMedPubMedCentral

134.

Wells CE, Bhaskara S, Stengel KR et al (2013) Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One 8(7):e68915. https://doi.org/10.1371/journal.pone.0068915CrossRefPubMedPubMedCentral

135.

Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M (2018) HDAC1, 2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia 32(1):49–60PubMed

136.

Johnson DP, Spitz GS, Tharkar S, Quayle SN, Shearstone JR, Jones S, McDowell ME, Wellman H, Tyler JK, Cairns BR (2015) HDAC1, 2 inhibition impairs EZH2-and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget 6(7):4863PubMed

137.

Ouaissi M, Silvy F, Loncle C, Ferraz da Silva D, Martins Abreu C, Martinez E, Berthezene P, Cadra S, Le Treut YP, Hardwigsen J, Sastre B, Sielezneff I, Benkoel L, Delgrande J, Ouaissi A, Iovanna J, Lombardo D, Mas E (2014) Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome. PLoS ONE 9(9):e108520. https://doi.org/10.1371/journal.pone.0108520CrossRefPubMedPubMedCentral

138.

Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn JS, Lee HY, Park CG, Kang J (2011) Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 25(6):1677–1681. https://doi.org/10.3892/or.2011.1236CrossRefPubMed

139.

Campos B, Bermejo JL, Han L, Felsberg J, Ahmadi R, Grabe N, Reifenberger G, Unterberg A, Herold-Mende C (2011) Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 102(2):387–392PubMed

140.

Dali-Youcef N, Froelich S, Moussallieh F-M, Chibbaro S, Noël G, Namer IJ, Heikkinen S, Auwerx J (2015) Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1 h-hrmas metabolomic profile in human gliomas. Sci Rep 5:9087PubMedPubMedCentral

141.

Liu Q, Zheng JM, Chen JK, Yan XL, Chen HM, Nong WX, Huang HQ (2014) Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1. Molecular Med Rep 10(4):2045–2050

142.

Zhu J, Wan H, Xue C, Jiang T, Qian C, Zhang Y (2013) Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration. Brain Res 1520:15–22PubMed

143.

Yang W, Liu Y, Gao R, Yu H, Sun T (2018) HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway. Cancer Lett 415:164–176PubMed

144.

Li S, Liu X, Chen X, Zhang L, Wang X (2015) Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling. Tumour Biol 36(12):9661–9665. https://doi.org/10.1007/s13277-015-3747-xCrossRefPubMed

145.

Lin TW, Chen MT, Lin LT, Huang PI, Lo WL, Yang YP, Lu KH, Chen YW, Chiou SH, Wu CW (2017) TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma. Oncotarget 8(34):56612–56625. https://doi.org/10.18632/oncotarget.17979CrossRefPubMedPubMedCentral

146.

Wang XQ, Bai HM, Li ST, Sun H, Min LZ, Tao BB, Zhong J, Li B (2017) Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells. Oncotarget 8(29):48027–48040. https://doi.org/10.18632/oncotarget.18227CrossRefPubMedPubMedCentral

147.

Yang R, Wu Y, Wang M, Sun Z, Zou J, Zhang Y, Cui H (2015) HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation. Oncotarget 6(10):7644–7656. https://doi.org/10.18632/oncotarget.3223CrossRefPubMedPubMedCentral

148.

Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao C, Wu WF, Chou HY, Lee YY, Lu KH, Chiou SH, Ma HI (2009) Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 380(2):236–242. https://doi.org/10.1016/j.bbrc.2009.01.040CrossRefPubMed

149.

Sayd S, Thirant C, El-Habr EA, Lipecka J, Dubois LG, Bogeas A, Tahiri-Jouti N, Chneiweiss H, Junier M-P (2014) Sirtuin-2 activity is required for glioma stem cell proliferation arrest but not necrosis induced by resveratrol. Stem Cell Rev Rep 10(1):103–113PubMed

150.

Park H-K, Hong J-H, Oh YT, Kim SS, Yin J, Lee A-J, Chae YC, Kim JH, Park S-H, Park C-K (2019) Interplay between TRAP1 and sirtuin-3 modulates mitochondrial respiration and oxidative stress to maintain stemness of glioma stem cells. Can Res 79(7):1369–1382

151.

Yamashita AS, da Costa RM, Borodovsky A, Festuccia WT, Chan T, Riggins GJ (2019) Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro-oncology 21(2):189–200PubMed

152.

Grinshtein N, Rioseco CC, Marcellus R, Uehling D, Aman A, Lun X, Muto O, Podmore L, Lever J, Shen Y (2016) Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget 7(37):59360PubMedPubMedCentral

153.

Singh MM, Johnson B, Venkatarayan A, Flores ER, Zhang J, Su X, Barton M, Lang F, Chandra J (2015) Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Neuro-oncology 17(11):1463–1473PubMedPubMedCentral

154.

Bose P, Dai Y, Grant S (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143(3):323–336PubMedPubMedCentral

155.

Wanczyk M, Roszczenko K, Marcinkiewicz K, Bojarczuk K, Kowara M, Winiarska M (2011) HDACi–going through the mechanisms. Front Biosci 16:340–359

156.

Hsu C-C, Chang W-C, Hsu T-I, Liu J-J, Yeh S-H, Wang J-Y, Liou J-P, Ko C-Y, Chang K-Y, Chuang J-Y (2016) Suberoylanilide hydroxamic acid represses glioma stem-like cells. J Biomed Sci 23(1):81PubMedPubMedCentral

157.

Pastorino O, Gentile MT, Mancini A, Del Gaudio N, Di Costanzo A, Bajetto A, Franco P, Altucci L, Florio T, Stoppelli MP (2019) Histone deacetylase inhibitors impair vasculogenic mimicry from glioblastoma cells. Cancers 11(6):747PubMedCentral

158.

Alvarez AA, Field M, Bushnev S, Longo MS, Sugaya K (2015) The effects of histone deacetylase inhibitors on glioblastoma-derived stem cells. J Mol Neurosci 55(1):7–20PubMed

159.

Orzan F, Pellegatta S, Poliani P, Pisati F, Caldera V, Menghi F, Kapetis D, Marras C, Schiffer D, Finocchiaro G (2011) Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 37(4):381–394PubMed

160.

Riva G, Butta V, Cilibrasi C, Baronchelli S, Redaelli S, Dalprà L, Lavitrano M, Bentivegna A (2016) Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity. Oncol Rep 35(5):2811–2824PubMed

161.

de Almeida SF, Caesar L, Jaeger M, Nör C, Abujamra AL, Schwartsmann G, de Farias CB, Brunetto AL, da Costa Lopez PL, Roesler R (2014) Inhibitory activities of trichostatin A in U87 glioblastoma cells and tumorsphere-derived cells. J Mol Neurosci 54(1):27–40

162.

Sun P, Xia S, Lal B, Eberhart CG, Quinones-Hinojosa A, Maciaczyk J, Matsui W, DiMeco F, Piccirillo SM, Vescovi AL (2009) DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells 27(7):1473–1486PubMedPubMedCentral

163.

Marampon F, Leoni F, Mancini A, Pietrantoni I, Codenotti S, Letizia F, Megiorni F, Porro G, Galbiati E, Pozzi P (2019) Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. J Cancer Res Clin Oncol 145(2):393–409PubMed

164.

Angeletti F, Fossati G, Pattarozzi A, Würth R, Solari A, Daga A, Masiello I, Barbieri F, Florio T, Comincini S (2016) Inhibition of the autophagy pathway synergistically potentiates the cytotoxic activity of givinostat (ITF2357) on human glioblastoma cancer stem cells. Front Mol Neurosci 9:107PubMedPubMedCentral

165.

Rotili D, Tarantino D, Carafa V, Paolini C, Jörg S, Jung M, Botta G, Di Maro S, Novellino E, Steinkühler C (2012) Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells. J Med Chem 55(18):8193–8197PubMed

166.

Nör C, Sassi FA, de Farias CB, Schwartsmann G, Abujamra AL, Lenz G, Brunetto AL, Roesler R (2013) The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells. Mol Neurobiol 48(3):533–543PubMed

167.

Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp H-G, Jugold M, Deubzer HE, Oehme I (2011) A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol 122(5):637PubMedPubMedCentral

168.

Asklund T, Kvarnbrink S, Holmlund C, Wibom C, Bergenheim T, Henriksson R, Hedman H (2012) Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer Res 32(7):2407–2413PubMed

169.

Sung GJ, Kim SH, Kwak S, Park SH, Song JH, Jung JH, Kim H, Choi KC (2019) Inhibition of TFEB oligomerization by co-treatment of melatonin with vorinostat promotes the therapeutic sensitivity in glioblastoma and glioma stem cells. J Pineal Res 66(3):e12556PubMed

170.

Booth L, Roberts JL, Conley A, Cruickshanks N, Ridder T, Grant S, Poklepovic A, Dent P (2014) HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biol Ther 15(3):305–316PubMed

171.

Pont LMB, Spoor JK, Venkatesan S, Swagemakers S, Kloezeman JJ, Dirven CM, van der Spek PJ, Lamfers ML, Leenstra S (2014) The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells. Genes Cancer 5(11–12):445

172.

Tung B, Ma D, Wang S, Oyinlade O, Laterra J, Ying M, Lv S-Q, Wei S, Xia S (2018) Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells. BMC Cancer 18(1):1025PubMedPubMedCentral

173.

Pont LMB, Kleijn A, Kloezeman JJ, van den Bossche W, Kaufmann JK, de Vrij J, Leenstra S, Dirven CM, Lamfers ML (2015) The HDAC inhibitors scriptaid and LBH589 combined with the oncolytic virus Delta24-RGD exert enhanced anti-tumor efficacy in patient-derived glioblastoma cells. PLoS ONE 10(5):e0127058

174.

Suraweera A, O'Byrne KJ, Richard DJ (2018) Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol 8:92. https://doi.org/10.3389/fonc.2018.00092CrossRefPubMedPubMedCentral

175.

Siegal T (2013) Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro-oncology 15(6):656–669PubMedPubMedCentral

176.

Siegal T (2014) Which Drug or Drug Delivery Method Can Change Clinical Practice for Brain Tumor Therapy? In: Drug Delivery to the Brain. Springer, pp 657–682. https://doi.org/10.1093/neuonc/not016

177.

Zhao J (2016) Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther 160:145–158PubMedPubMedCentral

178.

Di C, Zhao Y (2015) Multiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer. Experim Therapeutic Med 9(2):289–293

179.

Rabé M, Dumont S, Álvarez-Arenas A, Janati H, Belmonte-Beitia J, Calvo GF, Thibault-Carpentier C, Séry Q, Chauvin C, Joalland N (2020) Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death Dis 11(1):1–14

180.

Lee J-H, Choy ML, Marks PA (2012) Mechanisms of resistance to histone deacetylase inhibitors. In: Advances in cancer research, vol 116. Elsevier, pp 39–86. https://doi.org/10.1016/b978-0-12-394387-3.00002-1

181.

Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, Chen J, Sadée W, Byrd J, Marcucci G (2005) Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther 313(1):268–276PubMed

182.

Kim G-H, Choi SY, Oh T-I, Kan S-Y, Kang H, Lee S, Oh T, Ko HM, Lim J-H (2019) IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells. Int J Mol Sci 20(11):2679PubMedCentral

183.

Reddy RG, Surineni G, Bhattacharya D, Marvadi SK, Sagar A, Kalle AM, Kumar A, Kantevari S, Chakravarty S (2019) Crafting carbazole-based vorinostat and tubastatin-a-like histone deacetylase (HDAC) inhibitors with potent in vitro and in vivo neuroactive functions. ACS Omega 4(17):17279–17294PubMedPubMedCentral

184.

Elechalawar CK, Bhattacharya D, Ahmed MT, Gora H, Sridharan K, Chaturbedy P, Sinha SH, Jaggarapu MMCS, Narayan KP, Chakravarty S (2019) Dual targeting of folate receptor-expressing glioma tumor-associated macrophages and epithelial cells in the brain using a carbon nanosphere–cationic folate nanoconjugate. Nanoscale Adv 1(9):3555–3567

185.

Kumari S, Bhattacharya D, Rangaraj N, Chakarvarty S, Kondapi AK, Rao NM (2018) Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma. Nanomedicine 13(20):2579–2596PubMed

186.

Bhunia S, Vangala V, Bhattacharya D, Ravuri HG, Kuncha M, Chakravarty S, Sistla R, Chaudhuri A (2017) Large amino acid transporter 1 selective liposomes of L-DOPA functionalized amphiphile for combating glioblastoma. Mol Pharm 14(11):3834–3847PubMed

187.

Saha S, Venu Y, Bhattacharya D, Kompella SD, Madhusudana K, Chakravarty S, Ramakrishna S, Chaudhuri A (2017) Combating established mouse glioblastoma through nicotinylated-liposomes-mediated targeted chemotherapy in combination with dendritic-cell-based genetic immunization. Adv Biosyst 1(1–2):1600009

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer

Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration

Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors

ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy

A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men

Keynote webinar | Spotlight on antibody–drug conjugates in cancer